Novartis Ag (NVS) Research & Development (2009 - 2025)

Novartis Ag (NVS) has 15 years of Research & Development data on file, last reported at -$2.7 billion in Q2 2025.

• Quarterly Research & Development fell 15.21% year-over-year to -$2.7 billion in Q2 2025, while the trailing twelve-month figure through Jun 2025 was -$14.8 billion (down 51.1% YoY) and the FY2025 annual result came in at $11.2 billion, up 11.75% from the prior year.
• Research & Development grew to -$2.7 billion in Q2 2025 per NVS's latest filing, from -$4.8 billion in the prior quarter.
• The five-year high for Research & Development was -$194.0 million in Q3 2022, with the low at -$4.9 billion in Q4 2023.
• Average Research & Development over 5 years is -$1.7 billion, with a median of -$1.3 billion recorded in 2021.
• Year-over-year, Research & Development gained 13.39% in 2022 and plunged 2058.85% in 2023.
• Novartis Ag's Research & Development stood at -$240.0 million in 2021, then increased by 5.83% to -$226.0 million in 2022, then sank by 2058.85% to -$4.9 billion in 2023, then advanced by 1.87% to -$4.8 billion in 2024, then soared by 43.05% to -$2.7 billion in 2025.
• Business Quant data shows NVS's Research & Development at -$2.7 billion in Q2 2025, -$4.8 billion in Q4 2024, and -$2.4 billion in Q2 2024.